ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "quality of life"

  • Abstract Number: 1278 • ACR Convergence 2025

    Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus

    Emily Masi1, Kimberly Rapoza2, Tamar Rubinstein3, Kathy Kenney-Riley4 and Joyce Hui-Yuen5, 1Cohen Children's Medical Center, North New Hyde Park, NY, 2Mercy College, Dobbs Ferry, NY, 3Albert Einstein College of Medicine, White Plains, NY, 4Mercy University, Dobbs Ferry, NY, 5North Shore LIJ Health System, Great Neck, NY

    Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…
  • Abstract Number: 0640 • ACR Convergence 2025

    Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study

    Vibeke Strand1, Zahi Touma2, Anca Askanase3, Christopher Saffore4, Denise Kruzikas5, Karim Masri5, Siran Fang5, Yi Peng6, Patti Katz7 and Marta Mosca8, 1Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, 2University of Toronto, Toronto, ON, Canada, 3Columbia University Medical Center, New York, NY, 4AbbVie Inc., waukegan, IL, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., Maple Grove, MN, 7UCSF, San Rafael, CA, 8University of Pisa, Pisa, Pisa, Italy

    Background/Purpose: This analysis evaluated associations between clinically important improvements in patient-reported outcomes (PROs) and reduced disease activity from the phase 2 SLEek trial evaluating upadacitinib…
  • Abstract Number: 2441 • ACR Convergence 2025

    Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial

    Zahi Touma1, Cynthia Aranow2, Ioannis Parodis3, Rosalind Ramsey-Goldman4, Matthias Schneider5, Christine de La Loge6, Teri Jimenez7, Mina Nejati8 and Laurent arnaud9, 1University of Toronto, Toronto, ON, Canada, 2Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 3Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, 6UCB, Brussels, Belgium, 7UCB, Raleigh, NC, 8Biogen, Cambridge, MA, 9Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S 1109, Strasbourg, France, Strasbourg, France

    Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
  • Abstract Number: 1635 • ACR Convergence 2025

    Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases

    Daniela L. Guillen-Tejada1, Aura Matilde Jiménez-Garduño1 and Montserrat Lamuño Encorrada2, 1Universidad de las Américas Puebla, Puebla, Mexico, 2Hospital Ángeles Puebla, Puebla, Mexico

    Background/Purpose: Management of rheumatic diseases relies on chronic treatment, often with a greater risk of nonadherence. Frailty is characterized by decreased physiological function that increases patients’…
  • Abstract Number: 1262 • ACR Convergence 2025

    Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study

    Cristina Arriens1, Fredonna Carthen2, Alexandre Cammarata-Mouchtouris1, Judith James1, Joan Merrill3 and Motolani Ogunsanya4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
  • Abstract Number: 0634 • ACR Convergence 2025

    Association of Lifestyle and Integrative Health Practices with Health-Related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease

    Sarah Lieber1, Yongjay Kim2, Lucy Masto3, Amaya Smole4, Neha Nagpal1, Ranqing Lan1, Michael Parides1, Caroline Siegel1, Lisa Mandl1, Michael Lockshin5, Medha Barbhaiya1 and Lisa Sammaritano1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Englewood Cliffs, NJ, 3Hospital for Special Surgery, San Francisco, CA, 4Hospital for Special Surgery, Brooklyn, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Although available evidence supports the benefits of lifestyle interventions in SLE, the prevalence of lifestyle and integrative health behaviors and their association with health-related…
  • Abstract Number: 2429 • ACR Convergence 2025

    mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial

    Shanthini Kasturi1, Erin Morrissey1, Anna Deck2, Nina Gulati2, Zoe Gilbard2, Kiran Singh1, Monique Gore-Massy3, Faye Chiu4, Priscilla Calvache5, Jillian Rose-Smith5, Andre Ogura6, Lucas Ogura Dantas6, Wambui Machua7, Julia Nguyen8, Lisa Mandl5, Hocine Tighiouart1, Ludovic Trinquart2, Iris Navarro-Millan9 and Sara Folta10, 1Tufts Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA, 3N/A, West Orange, NJ, 4N/A, New York, NY, 5Hospital for Special Surgery, New York, NY, 6Ambulomics, Arlington, MA, 7Piedmont Healthcare, Atlanta, GA, 8Hospital for Special Surgery, New York, 9Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, 10Tufts Friedman School of Nutrition, Boston, MA

    Background/Purpose: Fatigue is a highly prevalent and debilitating symptom affecting up to 90% of individuals living with systemic lupus erythematosus (SLE). Despite its significant impact,…
  • Abstract Number: 1573 • ACR Convergence 2025

    Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival

    Katherine van der Wouden1, Georgy Gomon2, Rachel Knevel2, Michel Tsang-A-Sjoe3, Alexandre Voskuijl3 and Jeska de Vries-Bouwstra2, 1Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Patients with systemic sclerosis (SSc) face an uncertain long‑term outlook; understanding how their health‑related quality of life (HRQoL) changes over time can help them…
  • Abstract Number: 1261 • ACR Convergence 2025

    Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA

    Carter Pason1, Sarah Hopkins Gillespie1, Joelle Koplin2, Rachael Hewitt3, Christine Bundy3, Ethan Craig4, Laura Coates5, Jessica A. Walsh6 and Alexis Ogdie7, 1University of Pennsylvania, Philadelphia, PA, 2Penn Medicine, Philadelphia, PA, 3University of Cardiff, Cardiff, United Kingdom, 4University of Pennsylvania, Wallingford, PA, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 6Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE

    Background/Purpose: Approximately 60-70% of patients with PsA do not reach minimal disease activity (MDA) on therapy. However, in many cases, this may not be related…
  • Abstract Number: 0573 • ACR Convergence 2025

    Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

    Joseph F Merola1, Alexis Ogdie2, Alice B. Gottlieb3, Fabian Proft4, Nuala Brennan5, Alex Godwood5, Matthew R. Thomas5, Eva Cullen5, Kristian Reich6, Laura Coates7 and Laure Gossec8, 1Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 2University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, 4Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5MoonLake Immunotherapeutics AG, Zug, Switzerland, 6MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, 7Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 8Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France

    Background/Purpose: Sonelokimab (SLK) is a novel IL-17A- and IL-17F-inhibiting Nanobody designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain.…
  • Abstract Number: 0433 • ACR Convergence 2024

    Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study

    Eleonora Giacobbe1, Maria Chiara Gerardi2, Clizia Gagliardi2, Sara Benedetti2, Giuseppina Di Raimondo2, Assunta Ascione3, Monica Barichello2, Nicola Ughi4, Antonella Adinolfi2, Laura Belloli2, Cinzia Casu2, Maria Di Cicco2, Davide antonio Filippini2, Matteo Longhi2, Bianca Lucia Palermo2, Martina Schettino2, Giulia Segatto2, Elisa Verduci2 and Oscar Massimiliano Epis2, 1Niguarda Hospital, Milan, Milan, Lombardia, Italy, 2Niguarda Hospital, Milan, Milan, Italy, 3Niguarda Hospital, Milan, Milan, 4Niguarda Hospital, Milan, Mila, Italy

    Background/Purpose: As reproductive health is gathering attention in rheumatology and all medical fields, the male perspective on the matter is often overlooked as not directly…
  • Abstract Number: 1064 • ACR Convergence 2024

    Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center

    Shannon Herndon1, Jack Kimball1 and David Leverenz2, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, NC

    Background/Purpose: Palliative medicine prioritizes quality of life and relief of suffering in serious illness. Despite high morbidity and mortality in rheumatic disease, data suggests that…
  • Abstract Number: 1877 • ACR Convergence 2024

    Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities

    Aviraag Vijaya Prakash1, Vishwas Hosur Ravishankar2, Aishwarya Sudheer1 and Paramarajan Piranavan3, 1Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, 2St Vincents Hospital, Worcester, MA, 3University of Kentucky, Division of Rheumatology, Lexington, KY

    Background/Purpose: Rheumatoid Arthritis (RA) exhibits varied epidemiological patterns across states in the United States, influencing disability-adjusted life years (DALYs), incidence rates, prevalence, and mortality. This…
  • Abstract Number: 2453 • ACR Convergence 2024

    Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study

    Elvira Lesmana1, Ashley Keehn2, Anukul Karn3, Andrea Pauly4, Margaret Breen-Lyles2, Adam L Edwinson2, Madhusudan Grover5 and Ashima Makol5, 1Mayo Clinic, Rochester, MN, New York, NY, 2Mayo Clinic, Rochester, MN, Rochester, 3Mayo Clinic, Rochester, MN, Farmington Hills, MI, 4Mayo Clinic Rochester, Rochester, MN, 5Mayo Clinic, Rochester, MN, Rochester, MN

    Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
  • Abstract Number: 0449 • ACR Convergence 2024

    Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects

    Ana Cecilia Bardan-Inchaustegui1, Iris Jazmín Colunga Pedraza2, Rosa Icela Arvizu-Rivera2, Gisela Garcia-Arellano3, Griselda Serna-Peña4, Maria F. Elizondo-Benitez5, Aleydis Gonzalez Melendez2, Fernanda Massiel Garcia6 and Dionicio Galarza-Delgado7, 1Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, 5Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 6Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 30
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology